N. Kielerjensen et al., COMPARISON OF PROSTACYCLIN AND SODIUM-NITROPRUSSIDE FOR THE TREATMENTOF HEART-FAILURE AFTER CARDIAC-SURGERY, Journal of cardiothoracic and vascular anesthesia, 9(6), 1995, pp. 641-646
Citations number
55
Categorie Soggetti
Anesthesiology,"Peripheal Vascular Diseas","Cardiac & Cardiovascular System
Objective: To study the effects of the two vasodilators, prostacyclin
and sodium nitroprusside, on central hemodynamics in heart failure aft
er cardiac surgery. Design: Randomized cross-over study. Setting: Mult
i-institutional university hospital. Participants: Ten patients. Inclu
sion criteria: cardiac index less than 2.5 L/min/m(2); pulmonary capil
lary wedge pressure greater than 15 mmHg, systemic vascular resistance
index greater than 2,500 dynes . s . cm(-5)/m(2), and treatment with
inotropic support. Five patients were treated with intraaortic balloon
counterpulsation. Interventions: After control measurements, mean art
erial pressure was decreased by 10% to 20% with each vasodilator in ea
ch patient. Measurements and Results: Sodium nitroprusside induced dec
reases in mean pulmonary arterial pressure (-21%), pulmonary capillary
wedge pressure (-29%), central venous pressure (-17%), and systemic v
ascular resistance (-25%), and increases in cardiac output (+7%) and s
troke volume (+6%) compared with control. Prostacyclin decreased mean
pulmonary arterial pressure (-14%), pulmonary capillary wedge pressure
(-19%), central venous pressure (-7%), and systemic (-40%) and pulmon
ary (-25%) vascular resistances, whereas cardiac output (+25%) and str
oke volume (+22%) increased compared with control. Prostacyclin, compa
red with sodium nitroprusside, induced a more pronounced increase in c
ardiac output and stroke volume, associated with less pronounced decre
ases in cardiac filling pressures and more profound decreases in syste
mic and pulmonary vascular resistances. Conclusion: Prostacyclin appea
rs to be a useful agent, superior to sodium nitroprusside, in the trea
tment of postoperative heart failure in patients with normal or mildly
elevated cardiac filling pressures, where vasodilator treatment is in
dicated. (C) 1995 by W.B. Saunders Company